Fund Holdings — Wildcat Capital Management, LLC

Total Portfolio Value
$168.31M
Total Bought
$0
Total Sold
$5.12M
Net Transaction
-$5.12M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
RLX TECHNOLOGY INC(RLX)18,046,19518,046,195033,92739,88223.70%+5,955
UROGEN PHARMA LTD(URGN)495,606495,60605,4816,7904.03%+1,308
SILEXION THERAPEUTICS CORP113,428113,4280125920.05%-33
ACUREN CORP(TIC)1,500,0001,500,000016,68016,5609.84%-120
KRONOS BIO INC1,297,9590-1,297,9591,0710—-1,071
ALLOGENE THERAPEUTICS INC2,920,7872,920,78704,2643,1211.85%-1,143
CENTESSA PHARMACEUTICALS PLC281,8590-281,8594,0530—-4,053
FRONTIER GROUP HLDGS INC(ULCC)28,061,35128,061,3510121,786101,86360.52%-19,924
Page 1 of 1
Wildcat Capital Management, LLC — 13F Holdings — Q2 2025 | TickerTrail